BioNTX Joins Statewide Leaders at
THBI Policy Summit and Luminary Awards
|
The BioNTX team joined leaders from across the state for the Texas Healthcare and Bioscience Institute (THBI) Policy Summit and Luminary Awards in Austin, celebrating 30 years of advancing life sciences and healthcare innovation in Texas. North Texas was well represented, with Matt Crommett of Lyda Hill Philanthropies and LH Capital moderating a panel discussion, and Kelly Cloud and Rebekah Chenelle of the Dallas Regional Chamber among many regional leaders in attendance.
BioNTX congratulates North Texas Senator Tan Parker for being honored with THBI's Luminary Award, along with Rep. Ann Johnson of Houston and Casey McPherson of Austin, who were also awarded for their contributions to advancing the industry.
Beyond the celebration, the gathering examined the policy environment around academic research, clinical trials, newborn screening and access to treatments, and reinforced a bigger story: Texas' strength lies in collaboration among its regions, institutions, industry leaders and policymakers. At BioNTX, we are proud to build connections and elevate our regional ecosystem to help advance Texas' position as a global life sciences leader. The momentum is real, and the future is exciting!
|
Where Capital Meets Innovation:
BioNTX at Bloomberg Invest Dallas
|
North Texas is strengthening its position as a financial and investment hub, creating new opportunities for life sciences.
BioNTX was represented at Bloomberg Invest Dallas, joining investors, financial leaders, and industry executives to discuss emerging opportunities in capital markets.
With the arrival of NYSE Texas, the development of the Texas Stock Exchange, and major state investments in life sciences research through CPRIT and DPRIT, North Texas is well positioned to connect capital with innovation.
BioNTX is committed to connecting investors, innovators, and industry leaders to advance the region’s life sciences ecosystem.
|
BIO BREAK: Connect, Collaborate, Innovate
|
BIO BREAK brings the life sciences community together for an evening of connection and conversation. Attendees will have the opportunity to network with peers, share insights on emerging trends, and explore ideas driving collaboration and innovation across the ecosystem. The event is designed to strengthen professional relationships and support a more connected life sciences community in the region.
|
FORT WORTH
November 3, 2026
|
OncoSeer Diagnostics Selected for Mayo Clinic Platform Accelerate
|
OncoSeer Diagnostics has been selected to join the October 2026 Mayo Clinic Platform Accelerate cohort, an important opportunity to advance its innovative approach to cancer care.
Building on more than 12 years of foundational research at UT Southwestern Medical Center, OncoSeer is developing an AI-powered clinical decision support platform designed to help oncologists better predict, monitor and diagnose adverse immune reactions associated with cancer immunotherapies. The goal is to support more informed treatment decisions, expand patient access and reduce treatment interruptions.
Through the Mayo Clinic program, OncoSeer will gain access to specialized expertise and data resources to further develop and evaluate its technology. This milestone reflects a bigger story unfolding across North Texas: the growing ability of our research institutions and emerging companies to translate scientific discovery into solutions with the potential to improve patient outcomes.
At BioNTX, we are proud to celebrate OncoSeer's achievement and the continued advancement of our member companies on the national stage. Congratulations to the OncoSeer team! The momentum continues.
|
AstraZeneca and Oracle Partner to Advance AI-Driven Healthcare
|
AstraZeneca and Oracle Health and Life Sciences announced a collaboration to use AI, real-world data, and clinical expertise to improve patient care, optimize clinical trials, support earlier diagnosis, and strengthen drug safety monitoring. The first initiative will focus on improving hypertension care and clinical trial recruitment in Abu Dhabi.
|
Colossal Biosciences Advances Moa
De-Extinction Efforts With Rare Egg Acquisition
|
Dallas-based Colossal Biosciences acquired a rare moa egg and plans to return it to New Zealand, where the extinct flightless bird once lived. The egg will be placed under the care of Māori leaders and researchers to support cultural preservation and scientific study. The company is also pursuing efforts to bring the moa back through genetic engineering, with a potential timeline in the early 2030s.
|
Johnson & Johnson’s ICOTYDE Named
to TIME’s Best Inventions of 2026
|
Johnson & Johnson’s ICOTYDE, an oral peptide therapy for moderate to severe plaque psoriasis, was named to TIME’s Best Inventions of 2026 list in the medical and healthcare category. FDA approved in March 2026, the treatment represents a new approach to managing plaque psoriasis, a chronic inflammatory disease. The recognition highlights Johnson & Johnson’s continued efforts to advance treatment options and address unmet needs for patients living with the condition.
|
Nanoscope Therapeutics Publishes Preclinical Data
on Targeted Retinal Gene Delivery
|
Nanoscope Therapeutics announced the publication of preclinical research on its nonviral gene delivery platform designed to target specific areas of the degenerating retina. In animal studies, the approach demonstrated sustained visual response improvements for up to 52 weeks and restored localized retinal responses in a model of geographic atrophy. The findings support further development of targeted therapies for retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa,
|
Verily Health and PacBio Partner to
Advance AI-Driven Genomic Research
|
Verily Health and PacBio have announced a multi-year collaboration to integrate PacBio’s HiFi long-read sequencing technology with Verily’s healthcare data and AI platform. The partnership aims to combine genomic and clinical data to create AI-ready datasets that support biomedical research, drug discovery and the study of cancer, neurological disorders and rare diseases.
|
CRB’s 2026 Report Examines Key Trends
Shaping Life Sciences Manufacturing
|
CRB’s Horizons: Life Sciences 2026 report finds that life sciences companies are expanding manufacturing capacity and investing in advanced therapies, AI and automation despite rising costs and regulatory challenges. Based on a survey of more than 400 industry leaders, the report highlights growing demand for skilled workers, the importance of established biopharmaceutical hubs, and increased manufacturing interest across all surveyed drug modalities.
|
Hamilton and Ahlstrom Partner to
Advance Automated Blood Sample Processing
|
WuXi Biologics announced that its Wuxi Mashan drug substance and drug product manufacturing facilities successfully passed a two-week FDA GMP inspection. The result reinforces the company’s regulatory compliance record and its ability to reliably supply commercial biologics to the U.S. market.
|
TechFW Partners With Fort Worth Innovation Partnership
to Expand Startup Support
|
TechFW is partnering with the Fort Worth-Tarrant County Innovation Partnership to support startup growth and strengthen collaboration with Texas A&M University’s new Fort Worth campus. The agreement includes funding for TechFW’s ThinkLab and SmartStart programs and shared office space in downtown Fort Worth’s Switchyard Innovation District.
|
Alzheimer’s Association Launches Initiative
to Improve Dementia Care
|
The Alzheimer’s Association has launched the Brain Health & Quality Care Initiative to help health care organizations improve early detection, diagnosis and treatment of Alzheimer’s disease and other forms of dementia. The initiative will initially focus on primary care, providing clinicians with evidence-based guidance, training and resources, with Eisai and Eli Lilly and Company serving as its first founding partners.
|
Dallas EDC Moves Downtown to Support Economic Growth
|
Dallas Economic Development Corporation relocated to downtown Dallas to strengthen its connection to major development projects and institutions while continuing to attract new businesses, support existing companies, and expand economic opportunities throughout the city.
|
UT Arlington Receives Grant to Develop
AI Tools for Eye Disease Research
|
The University of Texas at Arlington is researching an artificial intelligence method to reduce radiation exposure during cardiac CT angiography without compromising diagnostic accuracy. Led by physics professor Mingwu Jin, the project will combine deep learning with advanced image reconstruction techniques to improve heart imaging and help doctors detect coronary artery disease.
|
UT Dallas Researcher Advances Search for New Cancer Treatments
|
The University of Texas at Dallas has recruited cancer researcher Alexander Adibekian, whose work focuses on identifying small molecules that interact with proteins in cancer cells. By combining mass spectrometry, proteomics and synthetic chemistry, his research aims to discover new drug candidates targeting cancer-related proteins that currently lack effective treatments.
|
UT Southwestern Study Finds Promising New Approach
to Advanced Kidney Cancer
|
A phase 2 clinical trial at UT Southwestern Medical Center found that targeted radiation followed by surgery may improve outcomes for patients with advanced kidney cancer that has spread into a major vein. Among the 23 patients studied, 71.4% remained cancer recurrence free one year after treatment. Researchers are planning a national trial to determine whether the approach can reduce surgical risks and expand treatment options.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
Brain Research & Innovation Network:
Grant Initiative of Texas (BRING IT)
Applications due November 13, 2026
|
The Rainwater Charitable Foundation has launched the Brain Research & Innovation Network: Grant Initiative of Texas (BRING IT) to support brain health and dementia research across Texas. The initiative will provide approximately 20 one-year seed grants of up to $100,000 each to Texas-based academic and nonprofit teams, helping advance promising research and prepare projects for future funding through the Dementia Prevention and Research Institute of Texas (DPRIT).
|
Upcoming Events & Opportunities
|
November Startup Bites is an upcoming workshop, luncheon, and networking event hosted by TechFW, a premier incubator, accelerator, and scaler for tech startups and entrepreneurs based right here in Fort Worth
November 6 | Fort Worth, TX
|
2026 Walk to End Alzheimer's - Dallas
The Walk to End Alzheimer’s, organized by the Alzheimer’s Association, is a community fundraising event held in Dallas to support care, research, and awareness for Alzheimer’s disease and other dementias.
November 7 | Dallas, TX
|
The Texas Life Science Forum, co-hosted by BioHouston and Rice Alliance, is the premier life science and healthtech event in Texas that brings together members from industry, emerging life science companies, academic and investors.
November 10 | Houston, TX
|
Securing AI in Healthcare
Join DFW Hospital Council for this webinar as a national IT expert will discuss content security and authorization security when it comes to AI.
November 12 | Virtual
|
Thank you for your support!
|
|